多肽vasostatin-1在心血管疾病诊治中的应用前景  

Prospect on the clinical application of vasostatin-1 in the diagnosis and treatment of cardiovascular disease

作　　者：郑刚[1] 

机构地区：[1]天津市第三医院心内科天津市老年病研究所天津市高血压防治中心,天津300250

出　　处：《世界临床药物》2013年第10期619-622,共4页World Clinical Drug

摘　　要：由心肌细胞分泌的一种具有生物活性的多肽vasostatin-1可非竞争性抑制肾上腺素受体,具有负性肌力、抗心肌缺血-再灌注损伤和抗心律失常作用。血浆vasostatin-1水平与急症患者预后相关,与冠心病患者冠状动脉存在病变和严重程度相关。本文综述vasostatin-1的生理作用、作用机制及其在临床预后判断中的价值。Vasostatin-l（VS-1） is a biological active peptides secreted by the myocardial cells. VS-1 can loncompetitively inhibit Badrenergic receptor, and has the function of negative inotropic, anti-myocardial ischemia- ~eperfusion injury and anti-arrhythmic effects. Plasma VS-1 concentration is interrelated with acute disease. In addition, VS-1 is concerned with the presence and severity of coronary artery disease in patients with coronary artery disease. This ~ eview describes the physiological role, mechanism and clinical prognostic value ofVS-1.

关 键 词：vasostatin—1 心血管疾病 生理作用 作用机制 预后 

分 类 号：R541[医药卫生—心血管疾病]